Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34278363.
- Also identified by DOI 10.1016/j.patter.2021.100325 and PMC identifier 8277549.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical <i>in silico</i> investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers.